Tisi Maria Chiara, Ausoni Giuseppe, Vita Maria Gabriella, Tartaglione Tommaso, Balducci Mario, Laurenti Luca, Chiusolo Patrizia, Hohaus Stefan, Sica Simona
Institute of Hematology, Catholic University S. Cuore, Rome.
Institute of Neurology, Catholic University S. Cuore, Rome.
Mediterr J Hematol Infect Dis. 2015 Mar 1;7(1):e2015025. doi: 10.4084/MJHID.2015.025. eCollection 2015.
Eleven cases of neurological defects in T-ALL patients treated with nelarabine have been described in the last 4 years, seven of these after stem cell transplantation (SCT) for T Lymphoblastic Lymphoma (T-LBL). Most of these patients had an unfavorable outcome or irreversible neurological damage. We now report the case of a 41-year-old woman suffering from T-LBL who presented with severe, but reversible myelopathy after receiving nelarabine-based treatment and mediastinal radiotherapy, and we provide a review of the literature on the topic.
在过去4年里，已有11例接受奈拉滨治疗的T-ALL患者出现神经功能缺损的病例被报道，其中7例是在接受T淋巴母细胞淋巴瘤（T-LBL）干细胞移植（SCT）后出现的。这些患者中的大多数预后不良或出现了不可逆的神经损伤。我们现在报告1例41岁患有T-LBL的女性患者，该患者在接受基于奈拉滨的治疗和纵隔放疗后出现了严重但可逆的脊髓病，并且我们提供了关于该主题的文献综述。
